- Japan
- /
- Medical Equipment
- /
- TSE:4549
Eiken Chemical Second Quarter 2025 Earnings: EPS: JP¥23.77 (vs JP¥22.87 in 2Q 2024)
Eiken Chemical (TSE:4549) Second Quarter 2025 Results
Key Financial Results
- Revenue: JP¥10.2b (down 1.8% from 2Q 2024).
- Net income: JP¥823.0m (down 2.9% from 2Q 2024).
- Profit margin: 8.1% (down from 8.2% in 2Q 2024). The decrease in margin was driven by lower revenue.
- EPS: JP¥23.77.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Eiken Chemical Earnings Insights
Looking ahead, revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Japan.
Performance of the Japanese Medical Equipment industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Be aware that Eiken Chemical is showing 1 warning sign in our investment analysis that you should know about...
Valuation is complex, but we're here to simplify it.
Discover if Eiken Chemical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4549
Eiken Chemical
Engages in the manufacturing and sale of clinical diagnostics in Japan.
Excellent balance sheet with moderate growth potential.